A team of researchers from Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College used genetic testing of cells found in cerebrospinal fluid to track certain brain tumors. In their paper published in the journal Nature, the group describes tests they conducted with cancer patients and analysis of their cerebrospinal fluid, and what they
Further exploration into the endpoints of the NRG Oncology/RTOG 0424 trial resulted in the discovery that MGMT promoter methylation is an independent prognostic biomarker of high-risk, low-grade glioma treated with temozolomide and radiation. This is the first study of its kind to validate the prognostic significance of MGMT promoter methylation in this patient population and
Using a novel imaging method, a Massachusetts General Hospital (MGH) research team is investigating the mechanisms behind a potential targeted treatment for a subtype of the deadly brains tumors called gliomas. In their report published in Nature Communications, the researchers describe using magnetic resonance spectroscopy (MRS) imaging—which reflects metabolic rather than structural aspects of tissues—to
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok